DKK1 for Gastric Cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug (DKN-01) is safe by itself and if the study drug may be taken with paclitaxel or pembrolizumab.
Who Can Participate in the Study?
- Have histologically confirmed recurrent or metastatic esophageal or GEJ squamous cell or adenocarcinoma
What is Involved?
If you choose to join this study you will:
- Be put into Parts A-F or monotherapy of this study
-- For parts A-E, you will be given DKN-01 through your vein on Day 1 and Day 15, and paclitaxel on Day 1, 8, 15 and 22 of each 28 day cycle
-- If you are put in Arm F, you will be given DKN-01 through your vein on Day 1, and 15, and pembrolizumab on Day 1 of each 21 day cycle
-- If you are put in the monotherapy sub-study, you will only get DKN-01 on Day 1 and 15 of each 28 Day cycle